| Naslov: | Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study |
|---|
| Avtorji: | ID Turnšek, Nina (Avtor)
ID Devjak, Rok (Avtor)
ID Edelbaher, Natalija (Avtor)
ID Osrajnik, Ilonka (Avtor)
ID Unk, Mojca (Avtor)
ID Vidovič, Dušanka (Avtor)
ID Jerič, Tina (Avtor)
ID Janžič, Urška (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (543,78 KB)
MD5: BEF2987F0DFD84362AB6D8BD229C973F
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions. Patients and methods. The REFLECT study (NCT04031898) is a retrospective medical chart review that explored real-life treatment and outcomes of EGFRm NSCLC patients receiving first-line (1L) first-/second-generation (1G/2G) EGFR TKIs in 8 countries. This study included adult patients with documented advanced/metastatic EGFRm NSCLC with 1L 1G/2G EGFR TKIs initiated between Jan 2015 – Jun 2018. We reviewed data on clinical characteristics, treatments, EGFR/T790M testing patterns, and survival outcomes. Here, we report data from 120 medical charts in 3 study sites from Slovenia. Results. The Slovenian cohort (median age 70 years, 74% females) received 37% erlotinib, 32% afatinib, 31% gefitinib. At the time of data collection, 94 (78%) discontinuations of 1L TKI, and 89 (74%) progression events on 1L treatment were reported. Among patients progressing on 1L, 73 (82%) were tested for T790M mutation yielding 50 (68%) positive results, and 62 (85%) received 2L treatment. 82% of patients received osimertinib. Attrition rate between 1L and 2L was 10%. The median (95% CI) real-world progression free survival on 1L EGFR TKIs was 15.6 (12.6, 19.2) months; median overall survival (95% CI) was 28.9 (25.0, 34.3) months. Conclusions. This real-world study provides valuable information about 1G/2G EGFR TKIs treatment outcomes and attrition rates in Slovenian EGFRm NSCLC patients. The reduced attrition rate and improved survival outcomes empha-size the importance of 1L treatment decision. |
|---|
| Ključne besede: | real-world study, non-small cell lung cancer, epidermal growth factor receptor, lung cancer |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 01.09.2022 |
|---|
| Založnik: | Association of Radiology and Oncology |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. 371-379 |
|---|
| Številčenje: | Vol. 56, no. 3 |
|---|
| Izvor: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-19797  |
|---|
| UDK: | 616.24-006 |
|---|
| ISSN pri članku: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2022-0025 |
|---|
| COBISS.SI-ID: | 118793219 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Opomba: | Soavtorji: Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic;
|
|---|
| Datum objave v DiRROS: | 25.07.2024 |
|---|
| Število ogledov: | 290 |
|---|
| Število prenosov: | 124 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
